Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…
#obesity #healthcare #pharmaceuticals #drugpricing #elililly #novonordisk #weightloss #publichealth #biotech
Thursday, January 15, 2026, 1:23 pm / permalink 17926 / 4 stories in 7 wks
Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)
GLP‑1 drugs associated with lower addiction risk in large study (4 days)
Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines (8 days)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.